Lateral flow devices (LFDs) are widely used point-of-care (POC) diagnostics. The basic LFD design remains largely unchanged since their first development and this limits their use in clinical applications due to lack of sensitivity. To enhance this, we report the use of laser-patterned geometric control barriers, in the form of a constriction, that leads to a slower flow rate and smaller test zone area. This high sensitivity LFD (HS-LFD) achieved 62% increase in test line colour intensity for the detection of procalcitonin (PCT) and reduced the LOD from 10 ng/ml to 1 ng/ml with contrived human samples
Alzheimer’s disease is caused by neurodegeneration resulting in cognitive decline, that has been linked to heightened systemic inflammation. Identification of the characteristic amyloid-β (Aβ) plaques in the brain is either by positron-emission tomography (PET) imaging or through its measurement in cerebrospinal fluid (CSF). A minimally invasive, cost-effective test that measures blood-based biomarker could predict the onset of Alzheimer’s earlier and therefore start therapies to improve patient prognosis. To this end, we have developed lateral-flow tests that measure vascular biomarkers, ICAM-1 and VCAM-1 and have validated their clinical use with serum samples.
We report a novel solution for semi-quantitative detection of C-reactive protein (CRP), a common inflammatory marker, using a multi-path lateral-flow device (LFD) fabricated via the precise partitioning of the single flow-path of a standard LFD using a laser direct-write technique. The multiple isolated flow-paths allow detection of different concentrations by individually setting different cut-off levels. The semi-quantitative readout is observed via simple appearance/absence of test lines without the need for a reader or further analyses. We have successfully demonstrated the use of these multi-path LFDs for semi-quantitative detection of CRP and will present validation in human samples.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.